Last month, we discussed Aduhelm, Biogen’s recently-approved Alzheimer’s drug that received pushback from medical professionals who believe the FDA put the cart ahead of the horse. Now, according to a New York Times article, two major medical centers, Cleveland Clinic and Mount Sinai, have decided not to administer the drug to patients.
Major Medical Centers Are Nixing Aduhelm
The controversial new Alzheimer’s drug may be FDA-approved, but there’s no shortage of critics.
Jul 21, 2021
INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
Read More